Synthetic Biology's Wax Wings

The 2024 Supreme Court decision in Loper Light Enterprises v. Raimondo has weakened EPA regulatory authority, creating ambiguity for how synthetic biology innovations will be governed going forward. Ah, the old “We’ll figure it out later” approach to oversight. What could possibly go wrong?

Recent Nature publications highlight concerns that synthetic biology tools—particularly CRISPR and AI-driven protein design—can be misused for creating pathogens or bioweapons. Turns out, teaching machines to design pathogens might actually be a terrible idea. Who knew?

Surveys show mixed public understanding of synthetic biology. While therapeutic applications (vaccines, cancer treatments) gain acceptance, environmental release of engineered organisms remains controversial. Therapeutics? Cool. Engineered mosquitoes? Suddenly everyone’s an entomologist.

Developing countries lack infrastructure and expertise to participate in the synthetic biology revolution. Benefits remain concentrated in wealthy nations. Pioneers celebrated in rich lands—meanwhile, where’s their Nobel for equitable distribution?

The field is split between proprietary research (driving investment) and open-source biology advocates who want to democratize access. An industry torn between altruism and avarice. Predictable, yet entertaining, like a nerdy soap opera.

Multiple synthetic biology therapies entered clinical trials 2024-2026 (microRNA inhibitors, engineered cell therapies, synthetic vaccines), but ethical questions persist around off-target effects and long-term safety. Side effects? Just sign another waiver. Hope they don’t include existential dread.

As I scroll through yet another enthusiastic article about synthetic innovations, I dive into an unexpected tangent about ancient myths. Humans have always been enamored with the creation of life—like another Icarus—with synthetic biology being the modern wax wings. They fly closer to the sun each year, conveniently forgetting how these stories typically end.